{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T14:44:07Z","timestamp":1784817847032,"version":"3.55.0"},"reference-count":20,"publisher":"Informa UK Limited","issue":"3","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Anticancer Therapy"],"published-print":{"date-parts":[[2026,3,4]]},"DOI":"10.1080\/14737140.2025.2590674","type":"journal-article","created":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T14:42:00Z","timestamp":1763044920000},"page":"295-299","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":3,"title":["Fixed-duration BTKi-venetoclax combinations in CLL: optimizing patient-centered care"],"prefix":"10.1080","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2795-6507","authenticated-orcid":false,"given":"Stefano","family":"Molica","sequence":"first","affiliation":[{"name":"Hull University Teaching Hospitals NHS Trust","place":["Hull, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Allsup","sequence":"additional","affiliation":[{"name":"Hull University Teaching Hospitals NHS Trust","place":["Hull, UK"]},{"name":"Hull York Medical School","place":["Hull, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,11,16]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2024000656"},{"key":"e_1_3_4_4_1","unstructured":"The European Commission approves IMBRUVICA\u00ae (ibrutinib) in a fixed-duration combination regimen for adult patients with previously untreated chronic lymphocytic leukaemia (CLL). News release. Johnson & Johnson; 2022 Aug 4 [cited 2025 Oct 8]. Available from: https:\/\/bit.ly\/3AMP4yh"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200006"},{"key":"e_1_3_4_6_1","volume-title":"Presented at: 2022 AACR Annual Meeting","author":"Allan JN","year":"2022","unstructured":"Allan JN, Flinn IW, Siddiqi T, et al. Fixed-duration ibrutinib + venetoclax for first-line treatment of chronic lymphocytic leukemia in patients with high-risk features: phase 2 CAPTIVATE study. Presented at: 2022 AACR Annual Meeting; 2022 Apr 8\u201313 [cited 2022 Aug 25]; New Orleans, LA. Abstract CT028."},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.06.016"},{"key":"e_1_3_4_8_1","unstructured":"Fixed-duration Calquence-based regimens approved in EU for patients with chronic lymphocytic leukaemia in the 1st-line setting. News release. AstraZeneca; 2025 Jun 6 [cited 2025 Oct 7]. Available from: https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2025\/fixed-duration-calquence-approved-in-eu-for-1l-cll.htmlhttps:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cll.pdf"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2409804"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.7036"},{"key":"e_1_3_4_11_1","unstructured":"Al-Sawaf O Stumpf J Zhang C et al. Fixed-duration versus continuous targeted treatment for previously untreated chronic lymphocytic leukemia: results from the randomized CLL17 trial. ASH; 2025 [cited 2025 Dec 6\u20139]. Available from: https:\/\/meetings-api.hematology.org\/api\/abstract\/vmpreview\/296353"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-203269"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00807"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2504341"},{"key":"e_1_3_4_15_1","volume-title":"XXI IWCLL","author":"Molica S","year":"2025","unstructured":"Molica S, Scalzulli PR, Scarf\u00f2 L, et al. Impact of dose intensity of ibrutinib on clinical outcomes of CLL patients: analysis of the EVIdeNCE study. In: XXI IWCLL; 2025 Sep 12\u201315; Krakov; Abstr 1709."},{"key":"e_1_3_4_16_1","volume-title":"XXI IWCLL","author":"Giza A","year":"2025","unstructured":"Giza A, Novak J, Ghia P, et al. Factors influencing physician\u2019s choice of fixed-duration ibrutinib+venetoclax or continuous ibrutinib monotherapy in the treatment of patients with previously untreated CLL: physician questionnaire results from the prospective phase 2 TAILOR study. In: XXI IWCLL; 2025 Sep 12\u201315; Krakov; Abstr 1409."},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00758"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023012221"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2024.2366534"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.01192"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17101708"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2025.288323"}],"container-title":["Expert Review of Anticancer Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737140.2025.2590674","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T02:46:13Z","timestamp":1772765173000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737140.2025.2590674"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,16]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,4]]}},"alternative-id":["10.1080\/14737140.2025.2590674"],"URL":"https:\/\/doi.org\/10.1080\/14737140.2025.2590674","relation":{},"ISSN":["1473-7140","1744-8328"],"issn-type":[{"value":"1473-7140","type":"print"},{"value":"1744-8328","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,16]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-10-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}